$163.20
1.53[0.95%]
Last update: 2:44PM Get Real Time Here
AbbVie Stock (NYSE:ABBV), Analyst Ratings, Price Targets, Predictions
AbbVie Inc has a consensus price target of $141.44, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from Barclays, Guggenheim, and Raymond James on March 27, 2024, March 22, 2024, and February 6, 2024. With an average price target of $191.33 between Barclays, Guggenheim, and Raymond James, there's an implied 17.74% upside for AbbVie Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Barclays
Guggenheim
Raymond James
Truist Securities
BMO Capital
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for AbbVie
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/27/2024 | ABBV | Buy Now | AbbVie | $162.51 | 19.99% | Barclays | Carter Gould | $185 → $195 | Maintains | Overweight | Get Alert |
| 03/22/2024 | ABBV | Buy Now | AbbVie | $162.51 | 16.92% | Guggenheim | Vamil Divan | $188 → $190 | Maintains | Buy | Get Alert |
| 02/06/2024 | ABBV | Buy Now | AbbVie | $162.51 | 16.3% | Raymond James | Gary Nachman | $181 → $189 | Maintains | Outperform | Get Alert |
| 02/06/2024 | ABBV | Buy Now | AbbVie | $162.51 | 19.99% | Truist Securities | Robyn Karnauskas | $180 → $195 | Maintains | Buy | Get Alert |
| 02/05/2024 | ABBV | Buy Now | AbbVie | $162.51 | 16.3% | Raymond James | Gary Nachman | $181 → $189 | Maintains | Outperform | Get Alert |
| 02/05/2024 | ABBV | Buy Now | AbbVie | $162.51 | 19.99% | BMO Capital | Evan David Seigerman | $187 → $195 | Maintains | Outperform | Get Alert |
| 02/05/2024 | ABBV | Buy Now | AbbVie | $162.51 | 13.84% | Barclays | Carter Gould | $175 → $185 | Maintains | Overweight | Get Alert |
| 01/29/2024 | ABBV | Buy Now | AbbVie | $162.51 | — | William Blair | Tim Lugo | — | Upgrade | Market Perform → Outperform | Get Alert |
| 01/23/2024 | ABBV | Buy Now | AbbVie | $162.51 | 7.69% | Barclays | Carter Gould | $170 → $175 | Maintains | Overweight | Get Alert |
| 12/18/2023 | ABBV | Buy Now | AbbVie | $162.51 | -4.01% | HSBC | Rajesh Kumar | $167 → $156 | Downgrade | Buy → Hold | Get Alert |
| 12/11/2023 | ABBV | Buy Now | AbbVie | $162.51 | 6.45% | Goldman Sachs | Chris Shibutani | → $173 | Upgrade | Neutral → Buy | Get Alert |
| 12/01/2023 | ABBV | Buy Now | AbbVie | $162.51 | 11.38% | Raymond James | Gary Nachman | $177 → $181 | Maintains | Outperform | Get Alert |
| 11/09/2023 | ABBV | Buy Now | AbbVie | $162.51 | -7.7% | Deutsche Bank | James Shin | → $150 | Initiates | → Hold | Get Alert |
| 10/30/2023 | ABBV | Buy Now | AbbVie | $162.51 | 20.61% | Morgan Stanley | Terence Flynn | $193 → $196 | Maintains | Overweight | Get Alert |
| 10/30/2023 | ABBV | Buy Now | AbbVie | $162.51 | 4.61% | Barclays | Carter Gould | $160 → $170 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 10/11/2023 | ABBV | Buy Now | AbbVie | $162.51 | 18.76% | Morgan Stanley | Terence Flynn | $189 → $193 | Maintains | Overweight | Get Alert |
| 09/29/2023 | ABBV | Buy Now | AbbVie | $162.51 | 8.92% | Raymond James | Gary Nachman | → $177 | Initiates | → Outperform | Get Alert |
| 07/28/2023 | ABBV | Buy Now | AbbVie | $162.51 | 4.61% | Piper Sandler | Christopher Raymond | $163 → $170 | Maintains | Overweight | Get Alert |
| 07/25/2023 | ABBV | Buy Now | AbbVie | $162.51 | — | William Blair | Tim Lugo | — | Initiates | → Market Perform | Get Alert |
FAQ
What is the target price for AbbVie (ABBV)?
The latest price target for AbbVie (NYSE: ABBV) was reported by Barclays on March 27, 2024. The analyst firm set a price target for $195.00 expecting ABBV to rise to within 12 months (a possible 19.49% upside). 24 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AbbVie (ABBV)?
The latest analyst rating for AbbVie (NYSE: ABBV) was provided by Barclays, and AbbVie maintained their overweight rating.
When was the last upgrade for AbbVie (ABBV)?
The last upgrade for AbbVie Inc happened on January 29, 2024 when William Blair raised their price target to N/A. William Blair previously had a market perform for AbbVie Inc.
When was the last downgrade for AbbVie (ABBV)?
The last downgrade for AbbVie Inc happened on December 18, 2023 when HSBC changed their price target from $167 to $156 for AbbVie Inc.
When is the next analyst rating going to be posted or updated for AbbVie (ABBV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbbVie, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbbVie was filed on March 27, 2024 so you should expect the next rating to be made available sometime around March 27, 2025.
Is the Analyst Rating AbbVie (ABBV) correct?
While ratings are subjective and will change, the latest AbbVie (ABBV) rating was a maintained with a price target of $185.00 to $195.00. The current price AbbVie (ABBV) is trading at is $163.20, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.